IBI362 / LY3305677
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
Mazdutide is a GLP-1/glucagon (oxyntomodulin analog) dual agonist developed by Innovent and Lilly, and the first of its class to gain approval, in China in 2025. Phase 2 data showed around 11% weight loss at 6 mg over 24 weeks; human evidence outside the approving jurisdiction remains limited to trial data. It is very frequently sold by research vendors, and the FDA has issued warning letters to US sellers.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published start, titration steps, and target dose, shown as reference. Included with membership.
Reference values as published in the research record — not a recommendation, instruction, or dose suggestion for any person. Not medical advice.
The live calculator — enter any vial size, diluent volume, and syringe size to see the draw computed — is included with membership.